Press Release June 13, 2016

PRESS: Billions at Stake as Biotech-Copycat Startups Chase Pharma Giants (Wall Street Journal)

Robert Cerwinski, a partner in Goodwin's IP Litigation Group, discusses the latest news on biosimilars, including why venture capitalists are hoping startups will compete with corporate giants in a new market for copycats of biotechnology’s biggest drugs. Cerwinski also discusses how billions of dollars are at stake as patents expire on many of biotech’s top medicines over the next several years.

Read the full Wall Street Journal article here.